Range Low Price High Price Comment
30 days $4.03 $5.16 Wednesday, 1st May 2024 BCRX stock ended at $4.57. This is 10.65% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 14.94% from a day low at $4.15 to a day high of $4.77.
90 days $4.03 $6.35
52 weeks $4.03 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Feb 25, 2021 $11.09 $11.64 $10.37 $10.47 7 776 575
Feb 24, 2021 $11.17 $11.85 $10.82 $11.81 4 659 455
Feb 23, 2021 $10.51 $11.29 $10.29 $11.09 7 440 900
Feb 22, 2021 $11.69 $12.41 $11.06 $11.19 8 277 463
Feb 19, 2021 $11.00 $11.61 $10.88 $11.53 6 267 494
Feb 18, 2021 $10.45 $10.96 $10.26 $10.80 6 022 577
Feb 17, 2021 $10.20 $10.88 $9.95 $10.66 5 944 205
Feb 16, 2021 $9.70 $10.47 $9.53 $10.34 7 321 895
Feb 12, 2021 $9.10 $9.76 $8.86 $9.57 8 617 509
Feb 11, 2021 $9.60 $9.73 $9.17 $9.20 5 822 907
Feb 10, 2021 $9.86 $10.07 $9.40 $9.55 5 162 829
Feb 09, 2021 $10.25 $10.26 $9.82 $9.90 5 323 223
Feb 08, 2021 $9.99 $10.41 $9.83 $10.25 6 102 237
Feb 05, 2021 $9.66 $10.16 $9.51 $9.79 7 074 508
Feb 04, 2021 $10.23 $10.28 $9.47 $9.65 9 409 717
Feb 03, 2021 $11.10 $11.15 $10.12 $10.30 9 683 827
Feb 02, 2021 $12.79 $12.90 $9.44 $10.53 27 988 107
Feb 01, 2021 $10.75 $12.04 $10.21 $11.85 36 590 180
Jan 29, 2021 $8.82 $9.06 $8.37 $8.52 4 892 982
Jan 28, 2021 $8.98 $9.24 $8.46 $8.71 4 746 056
Jan 27, 2021 $8.89 $9.16 $8.69 $8.76 5 490 375
Jan 26, 2021 $9.26 $9.49 $9.05 $9.16 4 747 195
Jan 25, 2021 $9.09 $9.25 $8.77 $9.16 5 084 658
Jan 22, 2021 $9.54 $9.78 $8.87 $9.21 9 044 606
Jan 21, 2021 $9.26 $9.33 $9.05 $9.15 4 017 691
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT